Skip to main content
. 2022 Dec 6;7(6):100639. doi: 10.1016/j.esmoop.2022.100639

Figure 2.

Figure 2

Kaplan–Meier estimates of (A) progression-free survival (PFS) and (B) overall survival (OS) with favezelimab plus pembrolizumab in patients with MSS mCRC by PD-L1 status.

CI, confidence interval; CPS, combined positive score; mCRC, metastatic colorectal cancer; MSS, microsatellite stable; PD-L1, programmed death-ligand 1.